Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
31 sty 2022 · The Clinical Trials Information System (CTIS) supports the flow of information between clinical trial sponsors, European Union (EU) Member States, European Economic Area (EEA) countries and the European Commission. CTIS went live with a searchable public website on 31 January 2022.
randomly test samples of centrally authorised products from the parallel distribution chain to verify their authenticity; carry out ad-hoc testing programmes for active pharmaceutical ingredients (API) sampled during good manufacturing practice (GMP) inspections.
This website allows you to search clinical trials initiated in the European Union and European Economic Area since its launch on 31 January 2022. Information on clinical trials initiated before 31 January 2022 can be found in the European Union Clinical Trials Register . For a mobile-friendly view, rotate your screen.
Emend jest lekiem przeciwwymiotnym, zapobiegającym nudnościom (uczucie mdłości) i wymiotom. Lek Emend stosuje się u pacjentów w wieku od 6 miesięcy celu zapobiegania nudnościom i wymiotom wywołanym chemioterapią (lekami stosowanymi w leczeniu raka).
The EU Clinical Trials Register provides a free and accurate search of clinical trials in European Union member states and the European Economic Area.
You can view information on individual clinical trials as soon as it becomes available, such as the EU clinical trial number, name and address of the trial sponsor, start and end dates of participant recruitment and of the trial itself.
